亿帆医药：关于全资子公司获得药品注册证书的公告

Core Viewpoint - Yifan Pharmaceutical announced that its wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the drug registration certificate for injectable isavuconazole from the National Medical Products Administration on September 15, 2025 [2] Group 1 - The drug registration certificate is a significant regulatory milestone for the company, indicating approval for the injectable formulation of isavuconazole [2] - This approval may enhance the company's product portfolio and market presence in the pharmaceutical industry [2] - The announcement reflects the company's ongoing commitment to developing innovative treatments and expanding its offerings in the biopharmaceutical sector [2]